BRIDGEBIO PHARMA INC. - COMMON STOCK
23.42
22-十一月-24 15:44:58
15 分钟延时
股票
+0.18
+0.77%
今日范围
22.47 - 23.65
ISIN
N/A
来源
NASDAQ
-
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
05 7月 2024 15:31:00 条件 Nasdaq GlobeNewswire
-
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
10 6月 2024 06:30:00 条件 Nasdaq GlobeNewswire
-
BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference
06 6月 2024 06:30:00 条件 Nasdaq GlobeNewswire
-
04 6月 2024 06:30:00 条件 Nasdaq GlobeNewswire
-
03 6月 2024 15:01:00 条件 Nasdaq GlobeNewswire
-
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
15 5月 2024 06:30:00 条件 Nasdaq GlobeNewswire
-
14 5月 2024 06:30:00 条件 Nasdaq GlobeNewswire
-
13 5月 2024 06:30:00 条件 Nasdaq GlobeNewswire
-
BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
02 5月 2024 06:30:00 条件 Nasdaq GlobeNewswire
-
02 5月 2024 06:00:00 条件 Nasdaq GlobeNewswire
-
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
10 4月 2024 06:30:00 条件 Nasdaq GlobeNewswire
-
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
20 3月 2024 06:30:00 条件 Nasdaq GlobeNewswire
-
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
05 3月 2024 22:53:56 条件 Nasdaq GlobeNewswire
-
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
04 3月 2024 15:17:36 条件 Nasdaq GlobeNewswire
-
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
04 3月 2024 01:30:00 条件 Nasdaq GlobeNewswire
-
BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
22 2月 2024 06:30:00 条件 Nasdaq GlobeNewswire